Algernon Appoints Novotech As CRO for Phase 2 Coronavirus Ifenprodil Trial

UF startup Algernon Pharmaceuticals Inc., a clinical-stage pharmaceutical development company, announced that it has chosen to appoint award winning Novotech as the contract research organization (CRO) for a planned physician initiated study of NP-120 (Ifenprodil) for COVID-19 infected patients in South Korea. Novotech is an internationally recognized full service CRO known for its experience across Australia, New Zealand, Asia and South Africa, representing emerging markets with a population base of over 3 billion people.